"Merck Surpasses Expectations with Strong Q4 Financial Results and Keytruda Sales Surge"

Merck announced its fourth-quarter and full-year 2023 financial results, reporting a 6% increase in fourth-quarter worldwide sales to $14.6 billion and a 1% increase in full-year worldwide sales to $60.1 billion. Key products like KEYTRUDA and GARDASIL/GARDASIL 9 saw significant sales growth, while LAGEVRIO sales declined. The company also provided a financial outlook for 2024, anticipating worldwide sales between $62.7 billion and $64.2 billion and non-GAAP EPS between $8.44 and $8.59. CEO Robert M. Davis expressed confidence in the company's momentum and highlighted their investments in research and development to drive impactful innovations.